Proteus Digital Health seeks to commercialize what it calls a new category of therapy: digital medicines. These offerings include widely used drugs, formulated with a sensor so they communicate when they have been swallowed; a wearable patch that detects medicines and captures physiologic response; mobile applications to support patient self-care and physician decision-making; and data analytics to serve the needs of health system managers. Some digital medicines are FDA-approved and are in commercial use in the United States currently. The company argues that data from both randomized clinical trials and real-world use demonstrate that patients have significantly improved outcomes using digital medicines (for example control of blood pressure) and that these outcomes can be sustained.
Proteus has over 450 issued patents and was founded in 2001 in the SF-bay area.
How Proteus Discover Works
Source: Crunchbase; Proteus; YouTube
FDA's new draft guidance could hinder applications for digital combination products
mobihealthnews - Feb 6, 2019
BC Platforms Partners with Proteus Genomics to Realize Precision Medicine by Combining Genomic Analysis and ...
PR Newswire (press release) - Aug 28, 2018
Digital Therapeutics Market Growth 2018-2025 Global Business Players – Proteus Digital Health, Inc., Omada Health ...
Chilton Times Journal - Aug 14, 2018
Global mHealth Market Growth Analysis (2018 – 2023)- Proteus Digital Health, Dexcom inc., Omada Health inc. and ...
MilTech - Aug 13, 2018
Beyond patient centricity – supporting the support network
pharmaphorum - Aug 13, 2018
New technology in Online Medical Market moving toward 2025 With New Procedures and Top venders like Online ...
Market Sector - Aug 11, 2018
IBA Completes Installation of Two Proteus One Proton Therapy Systems in Japan
Imaging Technology News (press release) (blog) - Jul 30, 2018
Global Ingestible Sensors Market 2018 – Proteus Digital Health, Capsovision, Given Imaging, Olympus Corporation
The Blamfluie (press release) (blog) - Jul 25, 2018
Proteus is Extending the Reach of the Digital Pill
Pharmaceutical Technology Magazine - Apr 26, 2018
*Based on Preferred Stock Price, Proteus Digital Health does not have a stock symbol since it is currently private and is yet to have an IPO.
- Andrew Thompson, Co-Founder & Chief Executive Officer
- George Savage, M.D., Co-Founder & Chief Medical Officer
- Mark Zdeblick, Ph.D., Co-Founder & Chief Technologist
- David O'Reilly, Chief Platform Officer
EquityZen does not have an affiliation with, formal relationship with, or endorsement from Proteus Digital Health or any companies featured above.
This profile is based on publicly available information and is intended to be informative in nature.
EQUITYZEN and logo are trademarks of EquityZen Inc. Other trademarks are property of their respective owners.